Tibet AIM Pharm. Inc. (SHE:002826)

China flag China · Delayed Price · Currency is CNY
21.50
-0.74 (-3.33%)
Mar 10, 2026, 3:04 PM CST
108.54%
Market Cap 4.03B
Revenue (ttm) 628.02M
Net Income (ttm) 85.87M
Shares Out 187.27M
EPS (ttm) 0.48
PE Ratio 45.20
Forward PE n/a
Dividend 0.10 (0.45%)
Ex-Dividend Date Jun 24, 2025
Volume 14,210,646
Average Volume 11,154,077
Open 22.43
Previous Close 22.24
Day's Range 21.00 - 22.55
52-Week Range 8.18 - 26.83
Beta 0.51
RSI 57.98
Earnings Date Apr 28, 2026

About Tibet AIM Pharm.

Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company’s products include Miglitol tablets for diabetes; ethnic medicine products, suitable for treating breast lobular hyperplasia, uterine fibroids, and ovarian cysts; gynecology and obstetrics; and NalMefene hydrochloride injection for various acute poisoning, such as alcohol, organic phosphor, CO, sedative-hypnotic, opioid substance, severe infection, shock, cord injury, and brain, as well as coma, spinal cord injury, ce... [Read more]

Sector Healthcare
Founded 2003
Employees 403
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002826
Full Company Profile

Financial Performance

In 2024, Tibet AIM Pharm.'s revenue was 651.88 million, a decrease of -2.27% compared to the previous year's 667.04 million. Earnings were 45.93 million, an increase of 198.50%.

Financial Statements

News

There is no news available yet.